VivoSeq
Oncology

Primary Peritoneal Carcinoma

0

Pipeline Programs↗

0

Active Trials↗

4

Companies Involved↗

Primary Peritoneal Carcinoma is an early-stage landscape with 0 programs across 4 companies. The most active players are Bristol-Myers Squibb, Gynecologic Oncology Group, Tracon Pharmaceuticals Inc..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

56/100

Attrition Rate

44/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalG

Gynecologic Oncology Group

0 programs

PreclinicalT

Tracon Pharmaceuticals Inc.

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed5 · 56%
Terminated3 · 33%
Withdrawn1 · 11%

Clinical Trials

Trial Activity

9 trials

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Completed·GGynecologic Oncology Group·Phase 2·NCT00671788·35 enrolled
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Completed·TTracon Pharmaceuticals Inc.·Phase 2·NCT01381861·23 enrolled
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Completed·WWashington University School of Medicine·Phase 2·NCT00868192·38 enrolled
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193297·50 enrolled
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT00179712·60 enrolled
Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02485990·24 enrolled
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT00179725·60 enrolled
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Terminated·Eli Lilly logoEli Lilly·Phase 2·NCT00082212·25 enrolled
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
Withdrawn·SSOTIO a.s.·Phase 3·NCT03905902

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)